Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

被引：1453

作者：

Wicki, Andreas ^{[1
]}

Witzigmann, Dominik ^{[2
]}

Balasubramanian, Vimalkumar ^{[3
]}

Huwyler, Joerg ^{[2
]}

机构：

[1] Univ Basel Hosp, Dept Internal Med, Div Oncol, CH-4031 Basel, Switzerland

[2] Univ Basel, Dept Pharmaceut Sci, Div Pharmaceut Technol, CH-4056 Basel, Switzerland

[3] Univ Helsinki, Fac Pharm, Div Pharmaceut Chem & Technol, Helsinki, Finland

来源：

JOURNAL OF CONTROLLED RELEASE | 2015年 / 200卷

关键词：

Cancer nanomedicine; Clinical trials; Nanoparticle; Liposome; Drug delivery; Targeting; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; POLYMERIC MICELLE FORMULATION; RECURRENT EPITHELIAL OVARIAN; TARGETED ONCOLYTIC POXVIRUS; ALBUMIN-BOUND PACLITAXEL; METASTATIC BREAST-CANCER; SQUAMOUS-CELL CARCINOMA; DRUG-DELIVERY; ANTITUMOR-ACTIVITY;

D O I：

10.1016/j.jconrel.2014.12.030

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharma-cokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic. (C) 2014 Elsevier B.V. All rights reserved.

引用

页码：138 / 157

页数：20

共 268 条

[1] Oncolytic viral therapies - the clinical experience [J].